Gliknik Inc.

Biopharmaceutical companies are entitled to set a path forward and then change course, just like anyone else, so it should not come as a surprise that Sirnaomics, Inc. reassessed its financing optio

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

IN VITRO DIAGNOSTICS Mergers & Acquisitions Clinical Genomics Technologies Pty. Ltd. Quest Diagnostics Inc. Enterix Inc. As part of a continued effort to focus on its Diagnostics Information Services

Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived